Compare AstraZeneca plc (AZN) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? AstraZeneca plc trades at $168.14 (market cap $253.13B), while First Trust NASDAQ 100 Technology Index Fund trades at $312.61. The key difference: AstraZeneca plc pays a 1.92% dividend while First Trust NASDAQ 100 Technology Index Fund pays none, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | QTEC | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $335.74 |
52-Week Low | $137.44 | $207.03 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
QTEC trades at $312.20, down 2.75% today amid neutral technical signals and bearish moving average pressure. The ETF provides equal-weighted exposure to Nasdaq-100 technology stocks, with recent news highlighting its role in the AI and semiconductor sector. Support levels at $310 and $307 provide near-term downside protection while resistance sits at $316 and $319.
The technology sector ETF faces headwinds from valuation concerns in AI-related stocks but maintains strategic positioning for long-term tech growth. Key risks include sector concentration and market volatility, while institutional interest remains steady given the fund's targeted exposure to leading technology companies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
